Duavee: Promising Results in Preventing Invasive Breast Cancer in Postmenopausal Women

A recent multi-center phase 2 clinical trial has revealed that Duavee, a medication already approved by the FDA for treating menopause symptoms, may also play a role in preventing invasive breast cancer. The study, conducted by researchers at Northwestern Medicine, involved 141 postmenopausal women diagnosed with ductal carcinoma in situ (DCIS), a non-invasive condition often seen as a precursor to more serious breast cancer.

The clinical trial, which took place across ten sites nationwide, randomized participants to receive either Duavee--a combination of conjugated estrogens and bazedoxifene--or a placebo for approximately four weeks between their diagnosis and scheduled breast surgery. Findings indicated that Duavee significantly inhibited cell growth in breast tissue, a critical factor associated with cancer progression. Notably, unlike other preventive medications for breast cancer, which often come with challenging side effects, Duavee was well tolerated among participants.

The lead investigator, a professor of breast surgery at Northwestern University Feinberg School of Medicine, expressed optimism about the potential of Duavee to not only alleviate menopausal symptoms but also reduce the risk of developing invasive breast cancer. This is particularly relevant for women at higher risk for breast cancer due to prior diagnoses of high-risk lesions such as atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS), as these individuals often face limited options for both menopausal treatment and breast cancer prevention.

While the preliminary results are promising, the lead investigator emphasized the need for a larger study with extended follow-up to thoroughly assess the efficacy of Duavee in breast cancer prevention. The fact that Duavee is already FDA approved and readily available adds to its appeal as a potential alternative treatment.

As the research continues, the findings will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, allowing for further discourse on the implications of this study within the medical community.